Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study

Diabetes Obes Metab. 2022 Jan;24(1):160-165. doi: 10.1111/dom.14547. Epub 2021 Oct 1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose
  • COVID-19 Vaccines / immunology*
  • COVID-19* / prevention & control
  • Diabetes Mellitus, Type 2*
  • Glycated Hemoglobin / analysis
  • Glycemic Control*
  • Humans
  • Immunogenicity, Vaccine*

Substances

  • Blood Glucose
  • COVID-19 Vaccines
  • Glycated Hemoglobin A